Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Imagion Signs First US Site Agreement for HER2 Breast Cancer Trial

IBX: $0.006 +50.00% · MC: $4M

Imagion Biosystems has signed its first US clinical trial site agreement for its MagSense HER2+ breast cancer imaging agent, with patient recruitment anticipated to begin shortly after site activation. Site-startup activities are underway at seven selected sites, and the trial is registered on ClinicalTrials.gov; the company expects the study to take 18–24 months.

Source announcements: 2026-11-17 08:56 to 2026-11-17 08:56 Sydney time
Story updated 2026-11-17 09:00 Sydney time
SourcesIBX First Site Agreement Advances Phase 2 Trial Plans
Comments